Literature DB >> 15138643

[Sepsis and multiple organ failure after BCG-instillation for bladder cancer].

A Elmer1, U Bermes, L Drath, E Büscher, A Viertel.   

Abstract

Local Bacillus Calmette-Guérin (BCG) immunotherapy is an effective and widely used treatment for superficial bladder carcinoma. Local side effects are frequent, whereas systemic side effects are rare, but more serious. Systemic BCG infection as a life-threatening complication of intravesical BCG instillation should be suspected in any patient who presents with persistent fever after BCG instillation for bladder cancer. A 62-year-old patient had been treated with 6 intravesical BCG instillations for recurrent, multifocal bladder carcinoma. 4 weeks after the last instillation, he presented with fever, malaise and scleral icterus. Laboratory tests revealed abnormal liver function tests, panzytopenia and signs of coagulation disorder. Bone marrow biopsy and liver biopsy showed noncaseating granulomas. Systemic BCG infection was suspected and antituberculous therapy combined with steroids was started. The patient developed severe sepsis and suffered from multiple organ failure. Despite partial improvement, the course was complicated by intracranial sinus thrombosis, and the patient died two month after admission.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138643     DOI: 10.1007/s00108-004-1205-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  18 in total

Review 1.  BCG intravesical instillations: recommendations for side-effects management.

Authors:  P Rischmann; F Desgrandchamps; B Malavaud; D K Chopin
Journal:  Eur Urol       Date:  2000       Impact factor: 20.096

2.  Disseminated infection after bacille Calmette-Guérin instillation for treatment of bladder carcinoma.

Authors:  J F Viallard; D Denis; J Texier-Maugein; M Parrens; I Faure; J L Pellegrin; B Leng
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

3.  Cortical evoked potentials by stimulation of the vesicourethral junction: clinical value and neurophysiological considerations.

Authors:  H Gänzer; H Madersbacher; E Rumpl
Journal:  J Urol       Date:  1991-07       Impact factor: 7.450

Review 4.  Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.

Authors:  J A Witjes; A P vd Meijden; F M Debruyne
Journal:  Urol Int       Date:  1990       Impact factor: 2.089

5.  Miliary tuberculosis due to intravesical bacillus Calmette-Guerin therapy.

Authors:  R C Gupta; R Lavengood; J P Smith
Journal:  Chest       Date:  1988-12       Impact factor: 9.410

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.

Authors:  D D Proctor; S Chopra; S C Rubenstein; J A Jokela; L Uhl
Journal:  Am J Gastroenterol       Date:  1993-07       Impact factor: 10.864

9.  Granulomatous hepatitis as a late complication of BCG immunotherapy.

Authors:  T Flippin; B Mukherji; Y Dayal
Journal:  Cancer       Date:  1980-10-15       Impact factor: 6.860

10.  Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.

Authors:  A Steg; C Leleu; B Debré; L Boccon-Gibod; D Sicard
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

View more
  3 in total

1.  Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.

Authors:  Pedro Dammert; Ziad Boujaoude; William Rafferty; Jonathan Kass
Journal:  BMJ Case Rep       Date:  2013-04-09

2.  Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy.

Authors:  Johannes Nemeth; Brigitte Stoiser; Heide-Maria Winkler; Leonard Müllauer; Wolfgang Graninger; Stefan Winkler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

3.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.